CAMP SEC Filing News — CAMP4 THERAPEUTICS CORPORATION

CAMP insider Gold Kelly (Chief Financial Officer) bought 10,000 shares (~$39.6K)

Gold Kelly, listed as Chief Financial Officer at Camp4 Therapeutics Corp, reported an open-market purchase of 10,000 CAMP shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

CAMP insider Schwab Andrew J. (Director) sold 400,000 shares (~$1.62M)

Schwab Andrew J., listed as Director at Camp4 Therapeutics Corp, reported an open-market sale of 400,000 CAMP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

CAMP insider Schwab Andrew J. (Director) sold 10 shares (~$45.00)

Schwab Andrew J., listed as Director at Camp4 Therapeutics Corp, reported an open-market sale of 10 CAMP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

CAMP insider Schwab Andrew J. (Director) sold 191,865 shares (~$879.7K)

Schwab Andrew J., listed as Director at Camp4 Therapeutics Corp, reported an open-market sale of 191,865 CAMP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

CAMP insider Tardiff Daniel (Chief Scientific Officer) sold 1,738 shares (~$8.3K)

Tardiff Daniel, listed as Chief Scientific Officer at Camp4 Therapeutics Corp, reported an open-market sale of 1,738 CAMP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

CAMP insider Form 4 filed for equity award, exercise, or tax withholding

5AM Partners VI, LLC (10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

CAMP insider Form 4 filed for equity award, exercise, or tax withholding

Schwab Andrew J. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

CAMP insider Young Richard A (Director) bought 16,378 shares (~$27.0K)

Young Richard A, listed as Director at Camp4 Therapeutics Corp, reported an open-market purchase of 16,378 CAMP shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

CAMP insider Maricich Yuri (Chief Medical Officer) bought 6,551 shares (~$10.8K)

Maricich Yuri, listed as Chief Medical Officer at Camp4 Therapeutics Corp, reported an open-market purchase of 6,551 CAMP shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

CAMP insider Gold Kelly (Chief Financial Officer) bought 6,551 shares (~$10.8K)

Gold Kelly, listed as Chief Financial Officer at Camp4 Therapeutics Corp, reported an open-market purchase of 6,551 CAMP shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

CAMP insider Mandel-Brehm Josh (Director, Chief Executive Officer) bought 6,551 shares (~$10.8K)

Mandel-Brehm Josh, listed as Director, Chief Executive Officer at Camp4 Therapeutics Corp, reported an open-market purchase of 6,551 CAMP shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

CAMP insider Form 4 filed for equity award, exercise, or tax withholding

WILLIAMS DOUGLAS E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

CAMP insider Form 4 filed for equity award, exercise, or tax withholding

Young Richard A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

CAMP insider Form 4 filed for equity award, exercise, or tax withholding

Schwab Andrew J. (Director, 10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

CAMP Form 144 filed for proposed insider sale by Daniel Tardiff (1,738 shares) ~$8.3K

Daniel Tardiff filed a Form 144 with the SEC indicating intent to sell CAMP (Camp4 Therapeutics Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

CAMP filed 8-K — material company event

Camp4 Therapeutics Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

CAMP filed 8-K — material company event

Camp4 Therapeutics Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

CAMP filed 8-K — material company event

Camp4 Therapeutics Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

CAMP filed 8-K — material company event

Camp4 Therapeutics Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

CAMP filed Quarterly Report (10-Q)

Camp4 Therapeutics Corp filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.